Trevena, Inc. (TRVN)
Largest Insider Buys in Sector
TRVN Stock Price History Chart
TRVN Stock Performance
About Trevena, Inc.
Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV027 for the treatment of acute lung injury contributing to acute respiratory distress syndrome and abnormal blood clotting in patients with COVID-19; TRV250, a G protein biased delta-opioid receptor …
Insider Activity of Trevena, Inc.
Over the last 12 months, insiders at Trevena, Inc. have bought $0 and sold $0 worth of Trevena, Inc. stock.
On average, over the past 5 years, insiders at Trevena, Inc. have bought $100,542 and sold $13,032 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 56,200 shares for transaction amount of $100,542 was made by Bourdow Carrie L. (President & CEO) on 2021‑06‑28.
List of Insider Buy and Sell Transactions, Trevena, Inc.
| 2022-06-28 | Sale | SVP, CFO | 31,785 0.0191% | $0.41 | $13,032 | -81.97% | ||
| 2021-06-28 | President & CEO | 56,200 0.0342% | $1.79 | $100,542 | -64.46% | |||
| 2019-05-31 | VP Fin,Princ Fin&Acct Officer | 15,000 0.0081% | $0.58 | $8,700 | -23.91% | |||
| 2019-02-01 | director | 200,000 0.2272% | $1.02 | $204,000 | -2.96% | |||
| 2019-02-01 | President & CEO | 100,000 0.1136% | $1.02 | $102,000 | -2.96% | |||
| 2018-03-22 | Sale | SVP, Bus Dev & Corp Planning | 10,000 0.0154% | $1.76 | $17,600 | -15.25% | ||
| 2017-02-10 | Sale | Sr. VP, Research & CSO | 47,398 0.0848% | $8.00 | $379,184 | -68.58% | ||
| 2016-11-09 | SVP, Chief Commercial Officer | 8,000 0.0147% | $4.34 | $34,720 | -29.31% | |||
| 2016-11-07 | President & CEO | 25,000 0.0488% | $4.10 | $102,500 | -19.45% | |||
| 2016-11-07 | SVP, Bus Dev & Corp Planning | 10,000 0.0196% | $4.12 | $41,200 | -19.45% | |||
| 2016-05-27 | President & CEO | 28,168 0.0541% | $7.08 | $199,429 | -12.32% | |||
| 2016-05-26 | President & CEO | 16,000 0.0311% | $7.20 | $115,120 | -12.68% | |||
| 2015-12-10 | Sale | Sr. VP,Clinical Dev. & CMO | 54,434 0.1227% | $10.55 | $574,279 | -34.14% | ||
| 2014-12-12 | Sr. VP,General Counsel & Secy | 6,000 0.0251% | $4.14 | $24,840 | +68.58% | |||
| 2014-12-10 | director | 2M 7.9332% | $4.00 | $8M | +64.91% | |||
| 2014-12-10 | director | 1M 3.9666% | $4.00 | $4M | +64.91% | |||
| 2014-12-10 | President & CEO | 16,000 0.0635% | $4.00 | $64,000 | +64.91% | |||
| 2014-12-10 | Sr. VP, Research & CSO | 10,000 0.0397% | $4.00 | $40,000 | +64.91% | |||
| 2014-12-10 | director | 19,800 0.0797% | $4.06 | $80,388 | +64.91% | |||
| 2014-12-10 | Sr. VP, Clinical Development | 1,250 0.005% | $4.00 | $5,000 | +64.91% |
Insider Historical Profitability
| New Enterprise Associates 12, Limited Partnership | director | 4811691 564.1346% | $1.60 | 2 | 1 | |
| Alta Partners VIII, L.P. | director | 4390262 514.7252% | $1.60 | 2 | 0 | |
| Forest Laboratories Holdings Ltd | director | 3393466 397.8584% | $1.60 | 1 | 0 | |
| HealthCare Ventures VIII, L.P. | director | 2446251 286.8045% | $1.60 | 1 | 0 | |
| Bourdow Carrie L. | President & CEO | 1301510 152.5923% | $1.60 | 2 | 0 | <0.0001% |
Institutional Investor Ownership
| Armistice Capital Llc | $709,145.00 | 8.4 | 1.54M | +93.25% | +$342,196.66 | <0.01 | |
| Renaissance Technologies | $70,000.00 | 0.83 | 152,425 | +0.58% | +$400.92 | <0.0001 | |
| BlackRock | $62,605.00 | 0.74 | 136,098 | +26.1% | +$12,957.72 | <0.0001 | |
| Citadel Advisors LLC | $53,471.00 | 0.63 | 116,242 | +72.05% | +$22,391.29 | <0.0001 | |
| Geode Capital Management | $53,188.00 | 0.63 | 115,575 | 0% | +$0 | <0.0001 |